Bradmer announces change to Board of Directors
"Mr. Rieder has played a valuable role in the development of Bradmer froman early stage, prior to its public listing, through its current level oforganizational and clinical maturity. We appreciate his continued support aswe move forward with the upcoming launch of our proposed Phase III clinicaltrial of Neuradiab in newly diagnosed glioblastoma multiforme," said Dr. AlanM. Ezrin, President and Chief Executive Officer of Bradmer. "We understand hisneed to focus on his primary interests and thank him for his pastcontributions."
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on thedevelopment and commercialization of new and innovative cancer therapies.Bradmer's lead clinical candidate, Neuradiab, was developed at Duke UniversityMedical Center as a proprietary therapy for a particularly aggressive form ofbrain cancer, glioblastoma multiforme. To date, over US$60 million in grantsand related support has driven research and development of the licensedtreatment, which has been delivered to over 200 patients with promisingresults and has completed Phase II clinical trials at Duke University. Bradmeris currently in the process of organizing a pivotal multi-center clinicaltrial of the licensed treatment. Neuradiab has been granted Orphan Drug Statusby both the U.S. Food and Drug Administration and the European MedicinesAgency.
Bradmer Pharmaceuticals Inc.'s common shares have not been registeredunder the Securities Act of 1933, as amended (the "Securities Act") or anystate regulatory agency in the United States. The resale or transfer by a U.S.investor of such common shares of Bradmer Pharmaceuticals Inc. is subject tothe requirements of Rule 904 of Regulation S of the Securities Act or suchother applicable exemption thereunder, and other applicable state securitieslaws.
Except for historical information, this press release may containforward-looking statements, which reflect the Company's current expectationregarding future events. These forward-looking statements involve risks anduncertainties, which may include but are not limited to, changing marketconditions, the successful and timely completion of clinical studies, theestablishment of corporate alliances, the impact of competitive products andpricing, new product development, uncertainties related to the regulatoryapproval process and other risks detailed from time to time in the Company'songoing quarterly and annual reporting.
SOURCE Bradmer Pharmaceuticals Inc.
You May Also Like